<DOC>
	<DOC>NCT02446015</DOC>
	<brief_summary>The purpose of this study is to evaluate the clinical benefits of SYSTANE速 ULTRA Lubricant Eye Drops using total ocular surface staining scores in subjects with dry eye administering it either as a scheduled regimen or as-needed after 28 days of treatment. This study will be conducted in the US and in Australia.</brief_summary>
	<brief_title>Clinical Evaluation Following Use of SYSTANE速 ULTRA in the Management of Dry Eye</brief_title>
	<detailed_description>This study will consist of a 14-day Run-in Phase (between the Screening Visit and Baseline/Visit 1) and a Treatment Phase. During the Run-in Phase, subjects will discontinue current artificial tears and be dispensed SYSTANE速 ULTRA to be administered 1 drop in each eye as needed (PRN). Subjects who meet the re-evaluation criteria after the Run-in Phase will be randomized in a 1:2 manner to receive treatment with SYSTANE速 ULTRA 4 times per day (QID) or PRN, respectively, for 28 days.</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Lubricant Eye Drops</mesh_term>
	<criteria>Willing and able to attend all study visits. Use of BAKfree artificial tear drops on an as needed basis, at least once a week, within 3 months prior to Screening Visit (maximum use of 4 drops a day). At least one '8 hour waking period' per week during the runin phase without using the provided artificial tear. Use provided artificial tear at least once a week during runin phase. Willing to take study treatment as directed for the entire study and able to complete the study diaries as required. Other protocolspecified inclusion criteria may apply. Use of artificial tears, as specified in the protocol. Use of topical ocular medications, as specified in the protocol. Women of childbearing potential who are pregnant, breast feeding, plan to become pregnant during the study, or not using adequate birth control methods to prevent pregnancy throughout the study. Any hypersensitivity to the use of the study product formulations or an allergy to any ingredient(s) contained within product formulations. Ocular abnormalities, infection, or active inflammation (not associated with dry eye) as specified in the protocol. Ocular or intraocular surgery or serious ocular trauma in either eye within the past 6 months prior to Screening Visit. Any medical condition (systemic or ophthalmic) that may preclude the safe administration of test article or safe participation in the study. Contact lens use within 2 weeks prior to Screening Visit, and unwilling to avoid contact lens use during the course of the study. Other protocolspecified exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>